Rabbit Recombinant Monoclonal IFITM2 antibody. Suitable for Flow Cyt (Intra), ICC/IF, WB and reacts with Transfected cell line - Human, Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Flow Cyt (Intra) | ICC/IF | WB | |
---|---|---|---|
Human | Tested | Tested | Tested |
Transfected cell line - Human | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Transfected cell line - Human | Dilution info 1/5000 | Notes - |
Species Human | Dilution info 1/50 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/250 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Transfected cell line - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Transfected cell line - Human | Dilution info - | Notes - |
IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol (PubMed:26354436, PubMed:33563656). Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV) (PubMed:26354436, PubMed:33239446, PubMed:33270927, PubMed:33563656). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry (PubMed:33563656). Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436).
IFITM3
Interferon-induced transmembrane protein 2, Dispanin subfamily A member 2c, Interferon-inducible protein 1-8D, DSPA2c, IFITM2
Rabbit Recombinant Monoclonal IFITM2 antibody. Suitable for Flow Cyt (Intra), ICC/IF, WB and reacts with Transfected cell line - Human, Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized A549 (human lung carcinoma epithelial cell) treated with 10ng/mL IFN-alpha 1 for 16 hours (Green) / Untreated A549 (Magenta) cells labelling IFITM2+IFITM3 with ab323747 at 1/50 dilution (1 ug) / Magenta and Green compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) (Black) and Grey isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody).
Goat anti-Rabbit IgG (Alexa Fluor® 647, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 647) preadsorbed ab150083) at 1/5000 dilution was used as the secondary antibody.
Flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized Isotype (upper left) / 293T (human embryonic kidney epithelial cell) cells transfected with an empty expression vector containing a Myc tag (upper middle) / 293T cells transfected with a IFITM1 expression vector containing a GFP tag (down left) / 293T cells transfected with a IFITM2 expression vector containing a GFP tag (down middle) / 293T cells transfected with a IFITM3 expression vector containing a GFP tag(down right) cells labelling IFITM2+IFITM3 with ab323747 at 1/5000 dilution (0.01 ug) compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) / Left isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody).
Goat anti-Rabbit IgG (Alexa Fluor® 647, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 647) preadsorbed ab150083) at 1/5000 dilution was used as the secondary antibody.
Flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized HeLa (human cervical adenocarcinoma epithelial cell) treated with 10ng/mL IFN-alpha 1 for 16 hours (Green) / Untreated HeLa (Magenta) cells labelling IFITM2+IFITM3 with ab323747 at 1/50 dilution (1 ug) / Magenta and Green compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) (Black) and Grey isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody).
Goat Anti-Rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081) at 1/5000 dilution was used as the secondary antibody.
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized A549 (human lung carcinoma epithelial cell) cells labelling IFITM2+IFITM3 with ab323747 at 1/250 (2.004 ug/ml) dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed antibody at 1/ 1000 2ug/ml dilution (Green).
Confocal image showing membranous and cytoplasmic staining in A549 cell line treated with IFN alpha (1000 U/ml) for 24h, and weak staining in A549 cell line (shown in green). The counterstain was observed in magenta. Nuclear DNA was labelled with DAPI (shown in blue). Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).
Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889 Anti-alpha Tubulin mouse monoclonal antibody - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at 1/ 200 2.5ug/ml dilution (Magenta). The Nuclear counterstain was DAPI (Blue).
Secondary antibody only control: Secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed at 1/ 1000 2ug/ml dilution.
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized HeLa (human cervical adenocarcinoma epithelial cell) cells labelling IFITM2+IFITM3 with ab323747 at 1/250 (2.004 ug/ml) dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed antibody at 1/ 1000 2ug/ml dilution (Green).
Confocal image showing membranous and cytoplasmic staining in HeLa cell line treated with IFN alpha 1 (10ng/ml) for 16h, and weak cytoplasmic staining in HeLa cell line (shown in green). The counterstain was observed in magenta. Nuclear DNA was labelled with DAPI (shown in blue). Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).
Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889 Anti-alpha Tubulin mouse monoclonal antibody - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at 1/ 200 2.5ug/ml dilution (Magenta). The Nuclear counterstain was DAPI (Blue).
Secondary antibody only control: Secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed at 1/ 1000 2ug/ml dilution.
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Negative control: Daudi
The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID: 34078739; PMID: 34321474; PMID: 30643282).
Lane 3 is incubated with Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 and lanes 1-2 are incubated with Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000.
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.
All lanes: Western blot - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (ab323747) at 1/1000 dilution
Lane 1: THP-1 (human monocytic leukemia monocyte) whole cell lysate at 20 µg
Lane 2: Daudi (human Burkitts lymphoma lymphoblast) whole cell lysate at 20 µg
Lane 3: Human liver tissue lysate at 20 µg
Lanes 1 - 2: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Lane 3: Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Observed band size: 15 kDa, 36 kDa
Exposure time: 70s
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID: 34078739; PMID: 34321474; PMID: 30643282).
The expression of IFITM2 and IFITM3 is up-regulated in response to IFN alpha 1 or IFN beta treatment (PMID: 34078739; PMID: 34321474; PMID: 30643282).
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.
Exposure time: Lanes 1-4: 15 seconds; Lanes 5-6: 5 seconds
All lanes: Western blot - Anti-IFITM2+IFITM3 antibody [EPR28942-88] (ab323747) at 1/1000 dilution
Lanes 1 and 3: Untreated A549 (human lung carcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2: A549 treated with 1000U/ml IFN alpha 1 for 24 hours whole cell lysate at 20 µg
Lane 4: A549 treated with 1000U/ml IFN beta 1 for 24 hours whole cell lysate at 20 µg
Lane 5: Untreated HeLa (human cervical adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 6: HeLa treated with 10ng/ml IFN alpha 1 for 16 hours whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Observed band size: 15 kDa, 36 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com